AdAlta

Updates

Board renewal and recently assembled clinical advisory team enhance leadership capabilities as “East-to-West” strategy and AD-214 are progressed

Expanded advisor network engaged to support “East to West” cellular therapy strategy

First non-binding term sheet executed for “East to West” cellular therapy strategy

AD-214 partnering to be supported by new advisors, stronger execution capabilities and new data from continuous manufacturing improvement program

New AdAlta Board members appointed, strategic review nearing completion